Release Date: 24/05/18 18:02 Summary: Managing Director and CEO succession Price Sensitive: Yes Download Document 175.03KB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%